Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVS Health Corporation stock logo
CVS
CVS Health
$104.54
-0.6%		$101.45
$61.19
▼
$110.68
$133.25B0.617.24 million shs7.08 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,149.28
-0.5%		$1,152.66
$623.78
▼
$1,249.45
$1.08T0.512.21 million shs2.88 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$47.20
-8.5%		$46.92
$35.12
▼
$64.16
$210.21B0.778.26 million shs26.74 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVS Health Corporation stock logo
CVS
CVS Health
-0.64%-2.88%-0.27%+27.30%+67.43%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.58%-3.92%-3.60%+19.07%+51.27%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-8.44%-3.20%-3.06%+7.65%-5.68%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CVS Health Corporation stock logo
CVS
CVS Health
$104.54
-0.6%		$101.45
$61.19
▼
$110.68
$133.25B0.617.24 million shs7.08 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,149.28
-0.5%		$1,152.66
$623.78
▼
$1,249.45
$1.08T0.512.21 million shs2.88 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$47.20
-8.5%		$46.92
$35.12
▼
$64.16
$210.21B0.778.26 million shs26.74 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CVS Health Corporation stock logo
CVS
CVS Health
-0.64%-2.88%-0.27%+27.30%+67.43%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.58%-3.92%-3.60%+19.07%+51.27%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-8.44%-3.20%-3.06%+7.65%-5.68%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CVS Health Corporation stock logo
CVS
CVS Health
2.88
Moderate Buy$105.671.08% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,283.6411.69% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.14
Hold$65.5638.91% Upside

Current Analyst Ratings Breakdown

Latest LLY, NVO, and CVS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
CVS Health Corporation stock logo
CVS
CVS Health
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$115.00 ➝ $122.00
7/20/2026
CVS Health Corporation stock logo
CVS
CVS Health
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
7/20/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
7/20/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
7/15/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$1,500.00 ➝ $1,600.00
7/14/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$1,300.00 ➝ $1,385.00
7/14/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$1,300.00 ➝ $1,385.00
7/14/2026
CVS Health Corporation stock logo
CVS
CVS Health
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$108.00 ➝ $118.00
7/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$1,250.00 ➝ $1,425.00
7/13/2026
CVS Health Corporation stock logo
CVS
CVS Health
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$103.00 ➝ $123.00
7/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$1,235.00 ➝ $1,273.00
(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CVS Health Corporation stock logo
CVS
CVS Health
$402.07B0.33$14.91 per share7.01$59.38 per share1.76
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B16.61$25.15 per share45.70$28.07 per share40.94
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.50$4.70 per share10.04$6.58 per share7.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CVS Health Corporation stock logo
CVS
CVS Health
$1.77B$2.2746.0512.461.020.72%11.88%3.54%8/5/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1540.8325.551.4334.98%105.77%23.76%8/5/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2611.0814.434.3037.23%63.31%22.19%8/5/2026 (Estimated)

Latest LLY, NVO, and CVS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
CVS Health Corporation stock logo
CVS
CVS Health
$1.86N/AN/AN/A$100.09 billionN/A
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.06N/AN/AN/A$20.69 billionN/A
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77N/AN/AN/A$10.88 billionN/A
5/6/2026Q1 2026
CVS Health Corporation stock logo
CVS
CVS Health
$2.21$2.57+$0.36$2.30$94.99 billion$100.43 billion
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CVS Health Corporation stock logo
CVS
CVS Health
$2.662.54%+5.87%117.18%4 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.60%+15.18%24.58%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.71%+21.74%41.08%N/A

Latest LLY, NVO, and CVS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.63%8/14/20268/14/20269/10/2026
7/10/2026
CVS Health Corporation stock logo
CVS
CVS Health
quarterly$0.66502.49%7/23/20267/23/20268/3/2026
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CVS Health Corporation stock logo
CVS
CVS Health
0.78
0.87
0.66
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56

Institutional Ownership

CompanyInstitutional Ownership
CVS Health Corporation stock logo
CVS
CVS Health
80.66%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
CVS Health Corporation stock logo
CVS
CVS Health
0.85%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
CVS Health Corporation stock logo
CVS
CVS Health
300,0001.28 billion1.27 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Novo Nordisk (NVO) Stock Looks Below Fair Value Despite Recent Setbacks
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novo-nordisk-nvo-stock-looks-211119093.html
Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail
July 31 at 8:08 PM  |  fiercebiotech.comF
Novo drug trial fail deals setback to bid to expand beyond obesity
July 31 at 8:08 PM  |  msn.comhttps://www.msn.com/en-us/health/other/novo-drug-trial-fail-deals-setback-to-bid-to-expand-beyond-obesity/ar-AA29arDv
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
July 31 at 8:08 PM  |  msn.comhttps://www.msn.com/en-us/health/other/novo-nordisk-s-stock-slumps-after-failed-trial-adding-to-the-company-s-woes/ar-AA298xmX
NVO stock plummets as Novo Nordisk heart drug fails late-stage trial
July 31 at 8:08 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/nvo-stock-plummets-as-novo-nordisk-heart-drug-fails-late-stage-trial/ar-AA29aoDW
Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?
July 31 at 8:08 PM  |  fool.comhttps://www.fool.com/investing/2026/07/31/novo-nordisk-shares-plunge-after-a-key-trial-fails-should-investors-buy-the-dip/
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
July 31 at 8:08 PM  |  stocktwits.comS
Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial
July 31 at 3:07 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-shares-sink-heart-182419372.html
Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings
July 31 at 1:30 PM  |  247wallst.comhttps://247wallst.com/investing/2026/07/31/novo-nordisk-vs-eli-lilly-the-better-buy-before-earnings/?utm_source=snapi
Novo Nordisk A/S (NYSE:NVO) Shares Gap Down - Should You Sell?
July 31 at 11:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/novo-nordisk-as-nysenvo-shares-gap-down-should-you-sell-2026-07-31/
Novo Nordisk Stock Drops as Heart Drug Fails Late-Stage Trial
July 31 at 10:56 AM  |  barrons.comhttps://www.barrons.com/articles/novo-nordisk-stock-drug-trial-e5f33f84
Novo Nordisk’s anti-inflammatory drug fails to reduce cardiovascular risk in late-stage trial
July 31 at 10:07 AM  |  wsau.comW
Novo Nordisk trial finds no heart benefit for ziltivekimab
July 31 at 10:07 AM  |  newsbytesapp.comN
Novo Nordisk’s ziltivekimab misses endpoint in Phase III cardiovascular outcomes trial
July 31 at 10:07 AM  |  thepharmaletter.comT
Novo Nordisk stock tumbles 10% as key trial misses goal
July 31 at 10:07 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-tumbles-10-120558178.html
Novo Nordisk drops as anti-inflammatory drug fails in late-stage trial
July 31 at 10:07 AM  |  seekingalpha.comhttps://seekingalpha.com/news/4622700-novo-nordisk-drops-trial-setback-anti-inflammatory-drug
Novo Nordisk ziltivekimab heart drug fails phase 3 trial
July 31 at 10:07 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novo-nordisk-ziltivekimab-heart-drug-124615748.html
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Amazon Earnings Offset Apple Weakness
July 31 at 10:07 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/exchange-traded-funds-equity-futures-130636476.html
NVO Stock Slumps After Late-Stage Trial Fails Primary Goal – Retail Says ‘Current Revenue Drivers’ Still Intact
July 31 at 10:07 AM  |  stocktwits.comS
Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results
July 31 at 9:17 AM  |  investopedia.comhttps://www.investopedia.com/market-update-novo-nordisk-stock-sinks-on-disappointing-heart-drug-trial-results-nvo-12031622
Novo Nordisk Stock Tumbles on Late-Stage Trial Results
July 31 at 8:31 AM  |  schaeffersresearch.comhttps://www.schaeffersresearch.com/content/news/2026/07/31/novo-nordisk-stock-tumbles-on-late-stage-trial-results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Coastal oil refinery with storage tanks, a gas flare stack, and tankers anchored offshore at dusk.
As the Iran War Resumes, 2 Energy ETFs Ride Oil’s Renewed Rally
By Jessica Mitacek | July 15, 2026
Illustrated data center corridor with server racks and cables leading to a glowing door labeled Anthropic.
Want Anthropic Exposure Before the IPO? These 2 AI Giants Are Already There
By Jessica Mitacek | July 8, 2026
Penguin Solutions logo overlaid on a data center hallway lined with server racks.
Why Penguin Solutions May Be the Smartest AI Infrastructure Stock
By Thomas Hughes | July 8, 2026
Comcast corporate logo and NBC peacock icon displayed against a colorful branded background.
Why the Comcast Spin-Off Won't Fix What's Actually Broken
By Chris Markoch | July 3, 2026
AST SpaceMobile logo with a satellite featuring large solar arrays orbiting above Earth in space.
AST SpaceMobile’s Next Launches Could Decide Whether Its Rally Regains Orbit
By Jessica Mitacek | July 13, 2026
CVS Health stock logo

CVS Health NYSE:CVS

$104.54 -0.68 (-0.65%)
Closing price 07/31/2026 03:59 PM Eastern
Extended Trading
$105.07 +0.53 (+0.50%)
As of 07/31/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, LTC pharmacies and on-site pharmacies, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was incorporated in 1996 and is headquartered in Woonsocket, Rhode Island.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,149.28 -5.69 (-0.49%)
Closing price 07/31/2026 03:59 PM Eastern
Extended Trading
$1,148.80 -0.48 (-0.04%)
As of 07/31/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$47.20 -4.41 (-8.55%)
Closing price 07/31/2026 03:59 PM Eastern
Extended Trading
$46.96 -0.24 (-0.51%)
As of 07/31/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas